Cardiovascular Business - March/April 2008 - (Page 35) enough attention,” Ellis said. He said the average interventional cardiologist has become more current and less fearful about using DES more often, but perhaps not the case with referring physicians. On the other hand, Rajan predicted that the market has plateaued, and DES will never achieve their initial popularity. He does not project that the market will decline any further, because the aging population and the obesity problem in the U.S. will demand these life-saving devices. The coming year will determine how the U.S. drug-eluting stent market will fare, which is always vulnerable to results of ongoing trials. However, now that the market has a third contender in Medtronic’s Endeavor, with a probable fourth in Abbott’s Xience, the cardiologists will have more choices. Finally, with clinical results trending toward the positive, the future is looking bright for this market. CardiovascularBusiness.com Cardiovascular Business 3 http://www.echotoolbox.com http://www.echotoolbox.com http://CardiovascularBusiness.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.